A practical reference on PNB-0408: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-28 and is reviewed periodically as new material appears.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
The terms "active" and "passive" are simple but important terms in the world of automotive safety. "Active safety" is used to refer to technology assisting in the prevention of a crash and "passive safety" to components of the vehicle (primarily airbags, seatbelts and the physical structure of the vehicle) that help to protect occupants during a crash. Crash avoidance systems and devices help the driver — and, increasingly, help the vehicle itself — to avoid a collision. This category includes: The vehicle's headlamps, reflectors, and other lights and signals The vehicle's mirrors The vehicle's brakes, steering, and suspension systems A subset of crash avoidance is driver assistance systems, which help the driver to detect obstacles and to control the vehicle. Driver assistance systems include:
Matches in Team Fortress Classic typically feature two teams, one red and one blue, and nine playable character classes. Each character class has a set of weapons and abilities unique to that specific class. This differentiation between classes makes for rock-paper-scissors-esque gameplay that requires teammates to work together in order to effectively achieve the objective. The class-system also encourages players to vary their selection of classes and utilize certain classes in conjunction with one another to gain the advantage. In Team Fortress Classic, a server can hold up to 32 players simultaneously, and matches can be played in a number of game modes, each featuring different objectives.
X-Ray crystal-structure analysis of plastocyanin at 2.7 Å resolution --- 707 citations Guss, J. M.; Freeman, H. C. (1983). "Structure of oxidised poplar plastocyanin at 1.6 Å resolution". J. Mol. Biol. 169 (2): 521–563. doi:10.1016/S0022-2836(83)80064-3. PMID 6620385. --- 642 citations Guss, J. M.; Harrowell, P. R.; Murata, M.; Norris, V. A.; Freeman, H. C. (1986). "Crystal structure analyses of reduced (CuI) poplar plastocyanin at 6 pH values". J. Mol. Biol. 192 (2): 361–387. doi:10.1016/0022-2836(86)90371-2. PMID 3560221. --- 388 citations Guss, J. M.; Bartunik, H. D.; Freeman, H. C. (1992). "Accuracy and precision in protein-structure analysis: restrained least-squares refinement of the structure of poplar plastocyanin at 1.33 Å resolution". Acta Crystallogr. B. 48 (6): 790–811. Bibcode:1992AcCrB..48..790G. doi:10.1107/S0108768192004270. PMID 1492962. --- 257 citations Kumar, V.; Dooley, D. M.; Freeman, H. C.; Guss, J. M.; Harvey, I.; McGuirl, M. A.; Wilce, M. C. J.; Zubak, V. M. (1996). "Crystal structure of a eukaryotic (pea seedling) copper-containing amine oxidase at 2.2 Å resolution". Structure. 4 (8): 943–955. doi:10.1016/S0969-2126(96)00101-3. PMID 8805580. --- 209 citations
The 2021 Copa América, relocated to Brazil at short notice, brought a third-place finish. Colombia beat Ecuador 1–0, drew 0–0 with Venezuela, then lost 2–1 to Peru and 2–1 to Brazil to finish third in Group B on four points. They eliminated Uruguay 4–2 on penalties in the quarter-finals in Brasília, a match in which David Ospina passed Carlos Valderrama's appearance record to become Colombia's most-capped player. Argentina won the semi-final 3–2 on penalties after a 1–1 draw, and Colombia beat Peru 3–2 in the third-place match, Luis Díaz scoring twice to finish as the tournament's joint leading scorer with Lionel Messi on four goals. Qualification for Qatar was lost to a scoring drought spanning seven consecutive matches. Although Colombia beat Venezuela 1–0 in their final fixture, they finished sixth on 23 points, one behind Peru, who took the play-off place. Rueda left shortly afterwards.
NQ01 metabolizes benzoquinone toward polyphenols (counteracting the effect of MPO). GSH is involved with the formation of phenylmercapturic acid. Genetic polymorphisms in these enzymes may induce loss of function or gain of function. For example, mutations in CYP2E1 increase activity and result in increased generation of toxic metabolites. NQ01 mutations result in loss of function and may result in decreased detoxification. Myeloperoxidase mutations result in loss of function and may result in decreased generation of toxic metabolites. GSH mutations or deletions result in loss of function and result in decreased detoxification. These genes may be targets for genetic screening for susceptibility to benzene toxicity.
Sources: en.wikipedia.org
The allergens in this family include allergens with the following designations: Amb a 1, Amb a 2, Amb a 3, Cha o 1, Cup a 1, Cry j 1, Jun a 1. Two of the major allergens in the pollen of short ragweed (Ambrosia artemisiifolia) are Amb a I and Amb a II. The primary structure of Amb a II has been deduced and has been shown to share ~65% sequence identity with the Amb a I multigene family of allergens. Members of the Amb a I/a II family include Tobacco (Nicotiana tabacum, Common tobacco) pectate lyase, which is similar to the deduced amino acid sequences of two pollen-specific pectate lyase genes identified in Lycopersicon esculentum (Tomato); Cry j I, a major allergenic glycoprotein of Cryptomeria japonica (Japanese cedar)—the most common pollen allergen in Japan; and P56 and P59, which share sequence similarity with pectate lyases of plant pathogenic bacteria. This enzyme belongs to the family of lyases, specifically those carbon-oxygen lyases acting on polysaccharides. The systematic name of this enzyme class is (1->4)-alpha-D-galacturonan lyase. Other names in common use include polygalacturonic transeliminase, pectic acid transeliminase, polygalacturonate lyase, endopectin methyltranseliminase, pectate transeliminase, endogalacturonate transeliminase, pectic acid lyase, pectic lyase, alpha-1,4-D-endopolygalacturonic acid lyase, PGA lyase, PPase-N, endo-alpha-1,4-polygalacturonic acid lyase, polygalacturonic acid lyase, pectin trans-eliminase, and polygalacturonic acid trans-eliminase. This enzyme participates in pentose and glucuronate interconversions.
Dunkin' Donuts' "It's Worth the Trip" campaign starred sleepy-eyed "Fred the Baker" and featured the catchphrase "Time to make the donuts”. It won honors from the Television Bureau of Advertising as one of the five best television advertisements of the 1980s. Fred the Baker was played by actor Michael Vale for 16 years until his retirement in 1997. The catchphrase was used in the title of founder William Rosenberg's autobiography Time to Make the Donuts: The Founder of Dunkin' Donuts Shares an American Journey.
Bobby's Vegas Gamble – Covers the opening of Mesa Grill Las Vegas. Restaurant Revamp – Flay tries to help a family restaurant. Chefography: Bobby Flay – Biography of Flay's life and career. Tasting Ireland – Flay takes a food tour of Ireland, his ancestral homeland. Food Network Awards – The Food Network recognizes people and places that have impacted the food world. All-Star Grill Fest: South Beach – Flay joins Paula Deen, Giada De Laurentiis, Alton Brown, and Tyler Florence for a barbecue. In October 2021, Variety reported that Flay would leave Food Network after a 27-year run, after he and the network failed to reach an agreement on a new contract. People reported that Flay had sought $100 million as part of the proposal. In November 2021, it was reported that Flay had signed a new three-year deal with Food Network.
As mayor, Newsom focused on development projects in Hunters Point and Treasure Island. He gained national attention in 2004 when he directed the San Francisco city–county clerk to issue marriage licenses to same-sex couples, violating a state law passed in 2000. Implementation of Care Not Cash, the initiative he had sponsored as a supervisor, began on July 1, 2004. As part of the initiative, 5,000 more homeless people were given permanent shelter in the city. About 2,000 people had been placed into permanent housing with support by 2007. Other programs Newsom initiated to end chronic homelessness included the San Francisco Homeless Outreach Team (SF HOT) and Project Homeless Connect (PHC), which placed 2,000 homeless people into permanent housing and provided 5,000 additional affordable rental units in the city. During a strike by hotel workers against a dozen San Francisco hotels, Newsom joined UNITE HERE union members on a picket line in front of the Westin St. Francis Hotel on October 27, 2004. He vowed that the city would boycott the hotels by not sponsoring city events at them until they agreed to a contract with workers; the contract dispute was settled in September 2006. In 2005, Newsom pushed for a state law to allow California communities to create policy restricting certain breeds of dogs. In 2007, he signed the law establishing Healthy San Francisco to provide city residents with universal health care, the first city in the nation to do so.
==== Cleavage of precursor proteins ==== Many proteins and hormones are synthesized in the form of their precursors - zymogens, proenzymes, and prehormones. These proteins are cleaved to form their final active structures. Insulin, for example, is synthesized as preproinsulin, which yields proinsulin after the signal peptide has been cleaved. The proinsulin is then cleaved at two positions to yield two polypeptide chains linked by two disulfide bonds. Removal of two C-terminal residues from the B-chain then yields the mature insulin. Protein folding occurs in the single-chain proinsulin form which facilitates formation of the ultimate inter-peptide disulfide bonds, and the ultimate intra-peptide disulfide bond, found in the native structure of insulin. Proteases in particular are synthesized in the inactive form so that they may be safely stored in cells, and ready for release in sufficient quantity when required. This is to ensure that the protease is activated only in the correct location or context, as inappropriate activation of these proteases can be very destructive for an organism. Proteolysis of the zymogen yields an active protein; for example, when trypsinogen is cleaved to form trypsin, a slight rearrangement of the protein structure that completes the active site of the protease occurs, thereby activating the protein. Proteolysis can, therefore, be a method of regulating biological processes by turning inactive proteins into active ones.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.